The use of biologic medications for the treatment of cutaneous immune-related adverse events secondary to immune checkpoint inhibitors: A single-institution real-life study

JAAD Case Rep. 2023 Nov 2:43:1-3. doi: 10.1016/j.jdcr.2023.09.041. eCollection 2024 Jan.
No abstract available

Keywords: biologics; cirAE; cutaneous immune-related adverse event; immune checkpoint inhibitor; immunotherapy; oncodermatology.

Publication types

  • Case Reports